Access to Medicine Foundation’s Post

As we delve into the dynamics of healthcare and pharmaceutical consumption, it's projected that by 2023, the utilization of antibiotics is set to witness a substantial surge across various countries. Notably, India is estimated to experience an 82% increase, while China is anticipated to observe a 59% upsurge. Similarly, Brazil is expected to encounter a 41% rise, and the United States is projected to witness a 22% spike in antibiotic usage. These statistics reflect the critical need for heightened awareness and proactive measures to address the escalating concerns associated with antimicrobial resistance. It's imperative to foster a culture of responsible antibiotic stewardship, promote stringent regulations, and prioritize the development of alternative therapies to mitigate the potential risks posed by increased antibiotic consumption. Let's collectively prioritize sustainable healthcare practices and collaborative efforts to safeguard the efficacy of antibiotics and ensure a healthier future for our global community. ~ Dr. Prashanthi #AntibioticAwareness #HealthcareTrends #PublicHealthInitiatives #GlobalHealth 🌎🔬

As we delve into the dynamics of healthcare and pharmaceutical consumption, it's projected that by 2023, the utilization of antibiotics is set to witness a substantial surge across various countries. Notably, India is estimated to experience an 82% increase, while China is anticipated to observe a 59% upsurge. Similarly, Brazil is expected to encounter a 41% rise, and the United States is projected to witness a 22% spike in antibiotic usage. These statistics reflect the critical need for heightened awareness and proactive measures to address the escalating concerns associated with antimicrobial resistance. It's imperative to foster a culture of responsible antibiotic stewardship, promote stringent regulations, and prioritize the development of alternative therapies to mitigate the potential risks posed by increased antibiotic consumption. Let's collectively prioritize sustainable healthcare practices and collaborative efforts to safeguard the efficacy of antibiotics and ensure a healthier future for our global community. ~ Dr. Prashanthi #AntibioticAwareness #HealthcareTrends #PublicHealthInitiatives #GlobalHealth 🌎🔬

Cost-Based Pricing For Innovative Medicines Is Unviable And Harmful https://lnkd.in/gdwD5X8d #marketingdigital #marketingstrategy #marketresearchcertification #marketresearchcourse #MarketResearch

APMP: Long-Term Solutions to combat the outbreak of Cholera, in Nigeria and Africa 1. Production of Affordable Oral Rehydration Solutions (ORS) and Antibiotics: The park will focus on manufacturing high-quality ORS and essential antibiotics that are crucial for cholera treatment. 2. Established Multiple Rapid Response Health Units: The pharma park will have specialized health units equipped with cholera treatment facilities and trained personnel. These units will be strategically located to respond quickly to outbreaks, providing immediate care and controlling the spread of the disease. 3. Collaborative Research and Development: The park will facilitate collaborations between pharmaceutical companies, research institutions, and government agencies to develop new vaccines and treatments for cholera. By implementing these measures, the Anambra Pharmaceutical Manufacturing Park is committed to fighting the cholera outbreak and improving public health in West Africa. Follow us for more details on how you can support the vision #HealthcareInnovation #AnambraPharmaPark #AfricaHealth

While tuberculosis (TB) can be cured, it still disproportionately affects low and middle-income nations, a situation worsened by the hurdles in securing reliable healthcare. At APIFA, we believe that local manufacturing of Active Pharmaceutical Ingredients (APIs) and other health products and technologies is pivotal in guaranteeing the consistent availability of crucial medications, which includes TB treatments, thereby enhancing the accessibility of these drugs for the populations most in need. Together, we can #EndTB. #WorldTBDay #APIForAfrica World Health Organization | Africa CDC

On July 25, a bipartisan House Committee roundtable met to discuss "Threats to Modern Medicine: Examining the Budgetary Effects of Antimicrobial Resistance (AMR) and the Broken Antibiotic Development Pipeline." Legislators expressed support for the PASTEUR Act, which aims to encourage innovative antimicrobial drug development by committing $6 billion to purchase new drugs for treating drug-resistant bacteria and fungi. These medications will be available at no cost to Medicare, Medicaid recipients, and Veterans Affairs beneficiaries. At TAXIS Pharmaceuticals, we believe antibiotics are the foundation of modern medicine and support the PASTEUR Act. Gregory G Mario, MBA, CEO of TAXIS Pharmaceuticals, emphasizes these points: ✔ Ensuring ROI for pharma companies is crucial for AMR research funding. ✔ Congress must lead in encouraging pharma companies to address AMR. ✔ We need new antibiotics and therapeutics to combat antibiotic resistance. ✔Funding the PASTEUR Act requires collaboration and negotiation. ✔ Investing in antibiotics can save lives and ensure economic productivity. Read our full statement here: https://bit.ly/4fDNMIC #AntibioticResistance #AMR #PASTEURAct #HealthcareInnovation #Pharma #PublicHealth #TAXISPharmaceuticals #innovation #medicine #globalhealth #pharmaceuticals #research

Substandard #antibiotics can exacerbate #antimicrobialresistance (AMR), a global health crisis in which widely used #antibiotics are becoming ineffective against the microbes they previously killed. #usp provides standards for identity, strength, quality, and purity that can assist manufacturers and national control laboratories testing these essential medicines. Visit our dedicated #antibiotics page including the newly updated #antibiotics families section to learn more about a specific antibiotic (including the active pharmaceutical ingredient (API) and any related impurities) https://lnkd.in/gJysafDd

🚀 Breaking Barriers in Healthcare: Colix Unveils Colistimethate Sodium 150mg for Injection Embark on a new era of healthcare excellence with Colix, where innovation meets precision. Introducing our groundbreaking solution: Colistimethate Sodium for Injection 150mg - lyophilized cake Why Colix? ✨ Precision Perfected: Witness healthcare at its finest. Our Colistimethate Sodium ensures not just treatment but a tailored, precise approach to critical infections. Every dose counts; every patient matters. 🌍 Setting Global Standards: At Colix, we don't just meet standards; we exceed them. Your trust in us is reciprocated with a commitment to quality that spans continents. Colistimethate Sodium 150mg: Beyond Medication In the pulse of healthcare evolution, we present more than a product; we present a revolution. Colix's Colistimethate Sodium 150mg is a testament to advancing patient outcomes and rewriting the narrative of infection treatment. Calling Healthcare Pioneers:👥 To all the trailblazers in healthcare, let's rewrite the future together. Colistimethate Sodium 150mg is not just a product; it's a partnership in pioneering excellence. Ready to experience a brighter, clearer world? 🌈 Comment below or visit www.fenixfarmacutica.com to discover more about the future of Colix - : Colistimethate Sodium for Injection 150mg - lyophilized cake.! 👇 So, if you're interested in learning more about this fantastic product, please don't hesitate to contact us. Let's help you take the first step towards better health! WhatsApp:- +91 9638392717 Email :- info@fenixfarmacutica.com #colix #colistimethate #injection #fenix #fenixfarmacutica #colixinnovation #healthawareness #healthcareinnovation #precisionmedicine #medicaladvancements #colistimethsodium #antibiotics #bacteria #bacterias #bacterialinfection #pharmaceutical #pharmaceuticalmanufacturing #lyophilization #lyophilizedcake #eugmp #southamerica #centralamerica #southafrica #westafrica #eastafrica #asiapacific #southeastasia #cis #emergingmarkets #india #export

Antibiotic resistance could cause over 39 million deaths by 2050, study says   Researchers have long flagged antimicrobial resistance as a public health concern, but this study is the first to analyze such trends around the world and over time.   The study looked at 520 million datasets, including hospital discharge records, insurance claims and death certificates from 204 countries. Using statistical modeling, the authors found that more than a million deaths related to antimicrobial resistance took place each year between 1990 and 2021. Since then, AMR deaths have only increased and will accelerate, according to the researchers.   https://lnkd.in/gfCNpAUP   Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) is a late-stage biopharmaceutical company dedicated to developing a new class of antibiotics for difficult-to-treat bacterial infections like C difficile.    #CDifficile #Antibiotics #ClinicalTrials #InfectionPrevention #AntimicrobialResistance #HealthcareInnovation #AcurxPharmaceuticals #ACXP Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP)

India has recently banned the use of the Aceclofenac 50mg + Paracetamol 125mg combination, marking a critical step in safeguarding public health. This decision stems from the potential risks associated with using this drug combination, particularly concerning liver toxicity. Why the Ban? Safety Concerns: Both Aceclofenac and Paracetamol are metabolized by the liver, increasing the risk of hepatotoxicity when combined, especially at higher doses. Ineffective Dosage: The lower dose of Paracetamol (125mg) in this combination may be subtherapeutic, potentially leading to reduced efficacy in pain relief and fever reduction, thus questioning its clinical usefulness. Global Practices: Several international regulatory bodies emphasize cautious use of NSAID-Paracetamol combinations, especially in vulnerable populations such as the elderly and those with liver conditions. #PharmaceuticalRegulations #DrugSafety #Pharmacovigilance #Healthcare #Pharmacology #PatientSafety #India